Trial Profile

A Phase 1/2 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 03 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gilteritinib (Primary) ; Cytarabine; Idarubicin
Indications Acute myeloid leukaemia
Focus Adverse reactions
Sponsors Astellas Pharma

Most Recent Events

01 Jan 2025 Interim results from this trial published in the International Journal of Hematology
16 Oct 2024 Status changed from active, no longer recruiting to completed.
20 Feb 2024 Planned End Date changed from 31 Dec 2024 to 31 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com